ADC Other Liab from 2010 to 2024

ADCT Stock  USD 2.03  0.04  2.01%   
ADC Therapeutics Other Liabilities yearly trend continues to be comparatively stable with very little volatility. Other Liabilities is likely to outpace its year average in 2024. From the period from 2010 to 2024, ADC Therapeutics Other Liabilities quarterly data regression had r-value of  0.58 and coefficient of variation of  157.56. View All Fundamentals
 
Other Liabilities  
First Reported
2010-12-31
Previous Quarter
29.1 M
Current Value
36.3 M
Quarterly Volatility
29.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check ADC Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ADC Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 5 M, Depreciation And Amortization of 2.7 M or Interest Expense of 48.6 M, as well as many indicators such as Price To Sales Ratio of 1.85, Dividend Yield of 0.0 or Days Sales Outstanding of 228. ADC financial statements analysis is a perfect complement when working with ADC Therapeutics Valuation or Volatility modules.
  
Check out the analysis of ADC Therapeutics Correlation against competitors.

Latest ADC Therapeutics' Other Liab Growth Pattern

Below is the plot of the Other Liab of ADC Therapeutics SA over the last few years. It is ADC Therapeutics' Other Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ADC Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Other Liab10 Years Trend
Slightly volatile
   Other Liab   
       Timeline  

ADC Other Liab Regression Statistics

Arithmetic Mean18,593,922
Geometric Mean6,081,855
Coefficient Of Variation157.56
Mean Deviation21,787,496
Median2,236,000
Standard Deviation29,296,549
Sample Variance858.3T
Range98.5M
R-Value0.58
Mean Square Error614.4T
R-Squared0.34
Significance0.02
Slope3,793,264
Total Sum of Squares12016T

ADC Other Liab History

202436.3 M
202329.1 M
202225.3 M
202165.1 M
2020100.5 M
20192.7 M
2018M

About ADC Therapeutics Financial Statements

ADC Therapeutics shareholders use historical fundamental indicators, such as Other Liab, to determine how well the company is positioned to perform in the future. Although ADC Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in ADC Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on ADC Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Other Liabilities29.1 M36.3 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for ADC Stock Analysis

When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.